Cell Viability Assays Market Report 2026

The cell viability assays market size has grown rapidly in recent years. It will grow from $1.73 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to expansion of in vitro research activities, increasing pharmaceutical R&D spending, growth in toxicology testing, rising use of cell culture models, availability of standardized assay kits.

The cell viability assays market size is expected to see strong growth in the next few years. It will grow to $2.72 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for high-throughput drug discovery, rising adoption of automated assay platforms, expansion of personalized medicine research, growing focus on assay miniaturization, increasing integration of imaging-based viability analysis. Major trends in the forecast period include increasing adoption of high-sensitivity viability assays, rising use of microplate-based detection systems, growing demand for multiparametric cell health analysis, expansion of drug screening applications, enhanced focus on reproducible assay protocols.

The increasing adoption of cell-based therapeutics is expected to drive the growth of the cell viability assay market in the coming years. Cell-based therapeutics involve the use of living cells to repair or replace damaged tissues, treat diseases, or restore normal physiological functions. The expansion of cell-based therapeutics is driven by advances in biotechnology, rising investments in regenerative medicine, growing acceptance and adoption of cell therapies, and improvements in cell engineering and manufacturing technologies. Cell viability assays play a critical role in supporting cell-based therapeutics by assessing the health, functionality, and safety of therapeutic cells, thereby improving treatment effectiveness and ensuring robust quality control. For instance, in 2023, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials increased by 10% in the third quarter of 2023, marking the first quarterly growth since Q3 2022. Therefore, the expansion of cell-based therapeutics is fueling the growth of the cell viability assay market.

Major companies operating in the cell viability assays market are focusing on the development of advanced cell screening technologies to enhance accuracy and accelerate drug discovery processes. Cell screening technologies strengthen cell viability assays by enabling high-throughput, precise, and rapid evaluation of cell health and responses, helping to optimize experimental workflows and improve therapeutic development outcomes. For instance, in May 2024, Arralyze, a Germany-based technology company, launched CellShepherd, an advanced single-cell analysis platform. The system employs proprietary nanowell glass arrays to miniaturize cell-based assays and allow real-time monitoring. It features autonomous and precise cell dispensing, sterile co-culturing capabilities, and imaging through brightfield and fluorescent channels. AI-driven analysis ensures accurate cell counting and tracking, addressing the growing demand for high-precision single-cell research in biomedical and life sciences applications.

In September 2025, Fluidic Sciences, a US-based life sciences company, acquired the business and assets of Sphere Bio for an undisclosed amount. Through this acquisition, Fluidic Sciences aims to accelerate single-cell analysis and protein interaction discovery, strengthen its research capabilities, expand its technology portfolio, and enhance its position in the biopharmaceutical and biotechnology markets. Sphere Bio is a US-based manufacturing company specializing in cell viability assays.

Major companies operating in the cell viability assays market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton, Dickinson, and Company, Agilent Technologies Inc., Lonza Group Ltd., PerkinElmer Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Beckman Coulter Inc., Promega Corporation, Abcam Limited, MP Biomedicals, Cayman Chemical Company, Cell Signaling Technology Inc., Enzo Biochem Inc., Creative Bioarray, Abnova Corporation, Biotium, Canvax, Nexcelom Bioscience LLC, G-Biosciences, AAT Bioquest Inc.

North America was the largest region in the cell viability assays market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell viability assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell viability assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cell viability assays market by increasing costs of imported reagents, assay kits, microplates, readers, and imaging systems used in research and diagnostics. Academic institutes and pharmaceutical companies in North America and Europe are most affected due to dependence on imported consumables, while Asia-Pacific faces higher costs for instrumentation. These tariffs are increasing per-assay costs and delaying equipment upgrades. However, they are also encouraging domestic production of assay kits, regional sourcing of consumables, and innovation in cost-efficient viability testing solutions.

The cell viability assays market research report is one of a series of new reports that provides cell viability assays market statistics, including cell viability assays industry global market size, regional shares, competitors with a cell viability assays market share, detailed cell viability assays market segments, market trends and opportunities, and any further data you may need to thrive in the cell viability assays industry. This cell viability assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell viability assays are techniques used to assess the ability of cells, tissues, or organs to remain alive or recover viability. These assays are employed to evaluate optimal growth conditions for cultured cells by examining their responses to external stimuli, chemicals, and therapeutic treatments when determining suitable culture environments.

The main products of cell viability assays include consumables and instruments. Consumables in cell viability assays are items that are single-use or require frequent replacement. These products are used across applications such as basic research, stem cell research, drug discovery and development, clinical and diagnostic applications, and others by end users including academic and research institutes, pharmaceutical and biotechnology companies, hospital and diagnostic laboratories, and others.

The cell viability assays market consists of revenues earned by entities by providing services such as assay development services, assay validation services, cell culture services, and data analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell viability assays market also includes sales of microscopes, imaging systems, incubators, plate readers, and automated liquid handling systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.